Clinical Research Directory

Inclusion Criteria * Female age: \> 18 to \< 38 years * The patient must have undergone not more than three consecutive unsuccessful IVF/ICSI cycles since the last ongoing pregnancy (whether fresh and/or several frozen ET resulted from these attempts) * BMI ≤29 Kg /m2 * Patients of ≤ 35 years old, body weight should be ≥ 60kg * Patients of \>35 years old, body weight should be \> 50 kg * Regular normo-ovulatory menstrual cycles (26-35 days) * Basal FSH \<10 IU/l, basal E2 \<60 pg/ml and basal Progesteone (\< 1.5 ng/mL) (normal cycle day-3 basal serum hormone levels), to be measured on cycle day 2 or 3 of the treatment cycle * Normal ultrasound scan (presence of both ovaries without evidence of abnormality within 6 months) * AFC \>7 and \< 20 * No pill within the 3 months before treatment * Signed informed consent Exclusion Criteria * Polycystic ovarian syndrome (PCOS) according to the Rotterdam classification (2004) * Oocyte donors * Poor responder patients (development of \<4 follicles in previous IVF/ICSI or cancelled cycles) * Endometriosis ≥ grade 3 * Contraindications to the use of gonadotropins * Abnormal vaginal bleeding of unknown cause * History of ovarian hyperstimulation syndrome (OHSS) or a previous ovarian stimulation cycle with more than 30 follicles of 11 mm or higher (as recommended by the Elonva® Summary of Product Characteristics) * A history of recurrent miscarriage (three or more consecutive miscarriages)